RedHill Biopharma Ltd.
RDHL
$1.02
-$0.01-0.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.08M | 6.81M | 9.55M | 8.80M | 8.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.08M | 6.81M | 9.55M | 8.80M | 8.04M |
| Cost of Revenue | 1.61M | 1.61M | 2.50M | 2.40M | 2.30M |
| Gross Profit | 2.47M | 2.47M | 4.31M | 3.66M | 3.01M |
| SG&A Expenses | 5.89M | -1.46M | 1.82M | 3.35M | 4.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.46M | -726.50K | 3.91M | 5.19M | 6.48M |
| Operating Income | -4.38M | -502.00K | -2.41M | -4.44M | -6.48M |
| Income Before Tax | -4.13M | 1.91M | -685.00K | -162.50K | 360.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.13 | 1.91 | -0.69 | -0.16 | 0.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.13M | -6.72M | -9.31M | -8.79M | -8.27M |
| EBIT | -4.38M | -502.00K | -2.41M | -4.44M | -6.48M |
| EBITDA | -4.21M | -494.00K | -2.56M | -4.47M | -6.38M |
| EPS Basic | -45.84K | -54.69K | -63.76K | -65.43K | -67.10K |
| Normalized Basic EPS | -1.43 | 1.07 | 0.39 | 0.29 | 0.18 |
| EPS Diluted | -45.84K | -54.69K | -63.76K | -65.43K | -67.10K |
| Normalized Diluted EPS | -1.43 | 1.07 | 0.39 | 0.29 | 0.18 |
| Average Basic Shares Outstanding | 6.77M | 4.84M | 6.05M | 5.42M | 4.80M |
| Average Diluted Shares Outstanding | 600.00 | 400.00 | 400.00 | 400.00 | 400.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |